Exagen Diagnostics, a medical diagnostic company focused in rheumatology, has announced the addition of the Avise SLE Prognostic panel to its testing services.
Designed to supplement the Avise SLE+ Connective Tissue diagnostic, Avise SLE Prognostic is a comprehensive prognostic panel that helps physicians assess potential risk for lupus nephritis, neuropsychiatric lupus, thrombosis and cardiovascular events.
The prognostic panel was developed in response to physician requests to help fulfill an unmet need in the rheumatology space.
Exagen Diagnostics president and CEO Ron Rocca said that the company is pleased to provide an additional tool to help support physicians with their clinical assessment and treatment of patients.
"This launch furthers our commitment to providing access to quality serologic testing to all patients. At Exagen, we truly are patient focused and discovery driven," Rocca added.